T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS
Sign Up to like & getrecommendations! Published in 2020 at "Schizophrenia Bulletin"
DOI: 10.1093/schbul/sbaa029.765
Abstract: Abstract Background Standard of care (SOC) antipsychotics exhibit efficacy at high dopamine D2 receptor occupancy (60%-80%), which is associated with increased risk of extrapyramidal symptoms (EPS). Lumateperone (lumateperone tosylate, ITI-007) is a mechanistically novel antipsychotic… read more here.
Keywords: schizophrenia; eps related; long term; treatment ... See more keywords